Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12166988 | PMC |
| http://dx.doi.org/10.1016/j.gendis.2025.101532 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Atopic dermatitis associated with systemic tacrolimus: Case report and review.
SAGE Open Med Case Rep
August 2025
Division of Dermatology, Department of Paediatrics, The Hospital for Sick Children, University of Toronto, ON, Canada.
A 10-month-old female was referred to dermatology clinic for evaluation of eczema, noted at 110 days after deceased-donor liver transplant while receiving systemic tacrolimus as monotherapy for posttransplant immunosuppression. She was seen and diagnosed with new onset atopic dermatitis (AD), thought to be in part related to her tacrolimus. After failing conventional treatment, her immunosuppression was switched from tacrolimus to sirolimus, and she received 1 dose of dupilumab.
View Article and Find Full Text PDFEfficacy of bleomycin and sirolimus in inhibiting CD31 endothelial cell proliferation in noninvoluting congenital hemangiomas.
Front Cell Dev Biol
August 2025
Department of Pediatric Surgery, West China Hospital of Sichuan University, Med-X Center for Informatics, Sichuan University, Chengdu, China.
Objective: Congenital hemangiomas are rare vascular anomalies that manifest at birth. Noninvoluting congenital hemangiomas present significant clinical challenges due to their persistence and associated complications. The mechanisms underlying congenital hemangiomas remain poorly understood, and current treatments have shown limited efficacy.
View Article and Find Full Text PDFEvaluation of Different Initial Doses of Envarsus in De Novo Kidney Transplant Recipients.
J Clin Med
August 2025
Institute of Health and Biomedical Research of Alicante, 03010 Alicante, Spain.
: Envarsus is a novel prolonged-release formulation of tacrolimus with enhanced bioavailability. The summary of product characteristics recommends an initial dose of 0.17 mg/kg/day for the prophylaxis of rejection in kidney transplant recipients, which may be excessive.
View Article and Find Full Text PDFA multimodal approach to smart and sustained drug delivery for corneal wound management: the GelPol nanoformulation.
Nanomedicine (Lond)
September 2025
Department of Pharmaceutical Sciences, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA.
Background: This study aims to develop a thermo-photo dual-stimuli-responsive hydrogel matrix and ROS-responsive engineered nanocarriers-based composite GelPol nanoformulation for corneal wound management. GelPol is composed of modified gelatin and poloxamer 407SH holding nanoparticles (NPs) loaded with dexamethasone, rapamycin, and ciprofloxacin.
Research Design And Methods: Dual-stimuli-responsive hydrogel and ROS-responsive NPs were synthesized and characterized.
Inhibition of Atg13-mediated autophagy enhances the anti-osteoclastogenic effect of sirolimus by counteracting its pro-autophagic activity.
Differentiation
September 2025
Department of Orthopedics, Fuzhou Second General Hospital, Fuzhou, 350007, Fujian, China. Electronic address:
Sirolimus can inhibit osteoclastogenesis. But sirolimus-activated autophagy is a favorable factor for osteoclastogenesis. This study aimed to explore the significance of autophagy in sirolimus-regulated osteoclastogenesis.
View Article and Find Full Text PDF